N-叔丁氧羰基-O-叔丁基-L-丝氨酸 | 13734-38-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丝氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-叔丁氧羰基-O-叔丁基-L-丝氨酸
• 中文别名: N-BOC-O-叔丁基-L-丝氨酸；BOC-丝氨酸；Boc-Ser(tBu)-OH
• 英文名称: N-(t-butyloxycarbonyl)-O-(t-butyl)-L-Serine
• 英文别名: Boc-Ser(tBu)-OH；Boc-Ser(OtBu)-OH；N-(tert-butoxycarbonyl)-O-(tert-butyl)-L-serine；Boc-L-Ser(tBu)-OH；(2S)-3-(tert-butoxy)-2-(tert-butoxycarbonylamino)-propanoic acid；(2S)-3-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 13734-38-8
• 化学式: C₁₂H₂₃NO₅
• 分子量: 261.318
• InChiKey: BPYLRGKEIUPMRJ-QMMMGPOBSA-N

物化性质

• 沸点：
  383.1±37.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储于0°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-Ser(tBu)-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-Ser(tBu)-OH
CAS number: 13734-38-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H23NO5
Molecular weight: 261.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-叔丁氧羰基-O-叔丁基-L-丝氨酸 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 Fmoc-Lys[Boc-Ser(t-Bu)]-OH
  参考文献：
  名称：

  通过化学选择性肽连接构建多种肽结构

  摘要：

  在此，我们报告了一种通过化学选择性肽连接构建不同肽结构的简便合成策略的发展。所涉及的关键进展是利用苯并呋喃部分作为肽水杨醛酯替代物，以及Dap-Ser/Lys-Ser二肽作为羟基氨基官能团，可以成功地将其引入到肽的侧链上，从而实现肽连接。通过该方法，设计并成功合成了侧链至侧链环肽、支链/桥接肽、带尾环肽和多环肽，并在连接位点成功合成了天然肽键。这一战略为合成肽的发展提供了另一种战略机遇。它还为新模式的 PPI 抑制剂的结构设计提供了灵感。

  DOI：

  10.1039/d1sc01174j
• 作为产物：
  描述：

  N-叔丁氧羰基-O-叔丁基-L-丝氨酸二环己胺盐 在 硫酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 N-叔丁氧羰基-O-叔丁基-L-丝氨酸
  参考文献：
  名称：

  TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS

  摘要：

  这项发明涉及以下给定的化合物（I）的公式或其药学上可接受的盐之一，作为药物；包含一个或多个具有公式（I）的化合物作为活性成分的药物组合物的公式（I），使用具有公式（I）的化合物制备旨在预防或治疗涉及异常细胞增殖的至少一种疾病的组合物，包含至少一种具有公式（I）的化合物的促凋亡组合物和/或抗增殖组合物，以及使用具有公式（I）的化合物作为促凋亡和/或抗增殖剂。

  公开号：

  US20090247472A1

文献信息

• Convergent Synthesis of Calcium-Dependent Antibiotic CDA3a and Analogues with Improved Antibacterial Activity via Late-Stage Serine Ligation
  作者：Delin Chen、Kathy Hiu Laam Po、Pilar Blasco、Sheng Chen、Xuechen Li

  DOI：10.1021/acs.orglett.0c01544

  日期：2020.6.19

  A convergent synthesis via the late-stage serine ligation of naturally occurring calcium-dependent antibiotic CDA3a and its analogues has been developed, which allowed us to readily synthesize the analogues with the variation on the lipid tail. Some analogues were found to show 100–500-fold higher antimicrobial activity than the natural compound CDA3a against drug resistant bacteria. This study will

  已经开发了通过后期丝氨酸连接天然存在的钙依赖性抗生素CDA3a及其类似物的聚合合成方法，这使我们能够容易地合成具有脂质尾巴变异的类似物。发现某些类似物对天然抗药性细菌的抗菌活性比天然化合物CDA3a高100-500倍。这项研究将增进我们对CDA3a的了解，并为进一步开发提供有价值的抗菌先导候选物。
• Total synthesis and antifungal evaluation of cyclic aminohexapeptides
  作者：Larry L. Klein、Leping Li、Hui-Ju Chen、Cynthia B. Curty、David A. DeGoey、David J. Grampovnik、Christina L. Leone、Sheela A. Thomas、Clinton M. Yeung、Kenneth W. Funk、Vimal Kishore、Edwin O. Lundell、Dariusz Wodka、Jon A. Meulbroek、Jeffrey D. Alder、Angela M. Nilius、Paul A. Lartey、Jacob J. Plattner

  DOI：10.1016/s0968-0896(00)00097-3

  日期：2000.7

  fungal infections continues to rise. Naturally occurring hexapeptide echinocandin B (1) has shown potent antifungal activity via its inhibition of the synthesis of beta-1,3 glucan, a key fungal cell wall component. Although this series of agents has been limited thus far based on their physicochemical characteristics, we have found that the synthesis of analogues bearing an aminoproline residue in the

  对治疗全身性真菌感染的新疗法的需求持续增长。天然存在的六肽棘皮菌素B（1）通过抑制β-1,3葡聚糖（一种重要的真菌细胞壁成分）的合成，显示出强大的抗真菌活性。尽管到目前为止，由于该试剂的理化特性而受到限制，但我们发现在“西北”位置带有氨基脯氨酸残基的类似物的合成可大大改善水溶性（> 5 mg / mL）。报道了基于整个细胞和一系列化合物的体内活性的合成和构效关系（SAR）。
• [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DE PI3K
  申请人：ALMIRALL SA

  公开号：WO2012146666A1

  公开（公告）日：2012-11-01

  New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

  披露了具有公式(I)化学结构的新型吡咯三嗪酮衍生物；以及它们的制备方法，包含它们的药物组合物以及它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的用途。
• BENZOTHIOPHENE DERIVATIVE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20160024060A1

  公开（公告）日：2016-01-28

  [Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.

  [待解决问题] 旨在提供一种具有PDE10A抑制活性的化合物，并具有新颖结构，或其同位素或药用可接受盐，以及一种以该化合物作为活性成分的药物组合物。 [解决方案] 本发明提供了一种由通用公式（I）表示的化合物或其药用可接受盐。
• A Positional Scanning Approach to the Discovery of Dipeptide-Based Catalysts for the Enantioselective Addition of Vinylzinc Reagents to Aldehydes
  作者：Christopher M. Sprout、Meaghan L. Richmond、Christopher T. Seto

  DOI：10.1021/jo051342w

  日期：2005.9.1

  crude form as catalysts for the asymmetric addition of vinylzinc reagents to aldehydes to give chiral allylic alcohols. Three sites of diversity on the ligands were optimized using a positional scanning approach. The optimized structure from the library, ligand 54, was found to catalyze the formation of 10 different (E)-allylic alcohols with enantioselectivities ranging from 90% to 95% ee. This ligand was

  通过平行固相法合成了基于二肽N-酰基乙二胺的配体的组合库。这些配体以粗制形式进行筛选，以作为乙烯基锌试剂不对称加成到醛中的催化剂，得到手性烯丙基醇。使用位置扫描方法优化了配体上的三个多样性位点。发现来自库的最佳结构，配体54，催化形成10种不同的（E）-烯丙基醇，其对映选择性为90％至95％ee。该配体对于芳族和α-支化醛以及衍生自大体积和直链末端炔烃的乙烯基锌试剂均有效。